RCS - Redx Pharma plc - Redx to Present at Keystone Symposia

Redx PharmaAnnouncement

03/05/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230503:nRSC1837Ya&default-theme=true

RNS Number : 1837Y  Redx Pharma plc  03 May 2023

REDX PHARMA PLC

("Redx" or "the Company")

 

Redx to Present Additional Preclinical Efficacy of RXC007 and DDR1/2
Inhibitors in Cancer-Associated-Fibrosis Models at The Resistant Tumour
Microenvironment, Keystone Symposia

Alderley Park, UK, 3 May 2023 Redx (AIM:REDX), the clinical-stage
biotechnology company focused on discovering and developing novel, small
molecule, highly targeted therapeutics for the treatment of cancer and
fibrotic disease announces additional preclinical data from the company's
fibrosis portfolio including data on lead asset RXC007, and Discodin Domain
Receptor (DDR) 1/2 inhibitors will be presented both orally and in a poster,
at The Resistant Tumour Microenvironment, Keystone Symposia (7-10 May 2022,
Vancouver, BC, Canada).

 

During the session on Wednesday 10(th) May 0830-1130am PDT: 'Friend or Foe:
Should we Target Cancer Associated Fibroblasts and the ECM?' Redx Senior
Scientist, Dr. Daniel Wilcock will discuss if targeting tumor fibrosis with
small molecule inhibitors of Rho Associated Coiled Coil Containing Protein
Kinase 2 (ROCK2) or DDR1/2 improves therapy response in preclinical models of
pancreatic ductal adenocarcinoma (PDAC) and triple negative breast cancer
(TNBC). Data presented will be from the Company's lead fibrosis asset, RXC007
as well as the DDR discovery programme, which further complements the data set
presented last year at the Extracellular Matrix Pharmacology Congress by
collaboration partner, the Garvan Institute of Medical Research.

 

In addition to Dr Wilcock's presentation, Redx will present a poster which
details the potential of RXC007 in an aggressive patient derived xenograft
model of PDAC in combination with standard of care (SoC) chemotherapy, and
DDR1/2 inhibition in a TNBC model in combination with anti-PD-1.

 

RXC007, the Company's lead asset, is a highly potent, selective and
orally-active ROCK2 inhibitor targeting multiple diseases associated with
fibrosis, initially being developed for interstitial lung diseases.  A Phase
2a study assessing RXC007 as a potential treatment for patients with
idiopathic pulmonary fibrosis (IPF) is expected to report topline data in Q1
2024.

 

Details of the presentation are as follows:

 

 Title:       Targeting tumor fibrosis with small molecule inhibitors of ROCK2 or DDR1/2
              improves therapy response in preclinical models of PDAC &TNBC

 Session:     Friend or Foe: Should we Target Cancer Associated Fibroblasts and the ECM?

 Day/Date:    Wednesday 10(th) May, 2023
 Time:        08:30-11:30 am PDT

 

  

A copy of the poster will be made available on the Company's website
following the presentation
at: https://www.redxpharma.com/scientific-publications/
(https://www.redxpharma.com/scientific-publications/)  

 

 For further information, please contact:

 Redx Pharma Plc                                                      T: +44 (0)1625 469 918

 UK Headquarters

 Caitlin Pearson, Head of Communications

 ir@redxpharma.com (mailto:ir@redxpharma.com)

 Lisa Anson, Chief Executive Officer

 US Office

 Peter Collum, Chief Financial Officer

 SPARK Advisory Partners (Nominated Adviser)                          T: +44 (0)203 368 3550
 Matt Davis/ Adam Dawes

 WG Partners LLP (Joint Broker)                                       T: +44 (0)203 705 9330
 Claes Spång/ Satheesh Nadarajah/ David Wilson

 Panmure Gordon (UK) Limited (Joint Broker)                           T: +44 (0)207 886 2500
 Rupert Dearden/ Freddy Crossley/ Emma Earl

 FTI Consulting                                                       T: +44 (0)203 727 1000
 Simon Conway/ Ciara Martin

 

About Redx Pharma Plc

Redx Pharma (AIM: REDX) is a clinical-stage biotechnology company focused on
the discovery and development of novel, small molecule, highly targeted
therapeutics for the treatment of cancer and fibrotic disease and the emerging
area of cancer-associated fibrosis, aiming initially to progress them to
clinical proof of concept before evaluating options for further development
and potential value creation. The Company's lead fibrosis product candidate,
the selective ROCK2 inhibitor RXC007, is in development for interstitial lung
disease being evaluated in a Phase 2a trial for idiopathic pulmonary fibrosis
(IPF) with topline data expected in Q1 2024. Redx's lead oncology product
candidate, the Porcupine inhibitor RXC004, being developed as a targeted
treatment for Wnt-ligand dependent cancers, is expected to report Phase 2 data
in combination with anti-PD-1 by end 2023.  Redx's third drug candidate,
RXC008, a GI-targeted ROCK inhibitor for the treatment of fibrostenotic
Crohn's disease, is progressing towards a CTA application in H2 2023.

 

The Company has a strong track record of discovering new drug candidates
through its core strengths in medicinal chemistry and translational science,
enabling the Company to discover and develop differentiated therapeutics
against biologically or clinically validated targets. The Company's
accomplishments are evidenced not only by its two wholly-owned clinical-stage
product candidates and rapidly expanding pipeline, but also by its strategic
transactions, including the sale of pirtobrutinib (RXC005, LOXO-305), a
non-covalent (reversible) BTK inhibitor now approved by the US FDA for adult
patients with mantle cell lymphoma previously treated with a covalent BTK
inhibitor, and AZD5055/RXC006, a Porcupine inhibitor targeting fibrotic
diseases including IPF, which AstraZeneca is progressing in a Phase 1 clinical
study. In addition, Redx has forged collaborations with Jazz Pharmaceuticals,
which includes JZP815, a pan-RAF inhibitor developed by Redx which Jazz is now
progressing through Phase 1 clinical studies, and an early stage oncology
research collaboration.

 

To subscribe to Email Alerts from Redx, please visit:
www.redxpharma.com/investor-centre/email-alerts/
(http://www.redxpharma.com/investor-centre/email-alerts/)

 

 

 

 

 

 

 

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRANKBBNOBKDKPK